The Golden Rule of IVF Stimulation: Why “More” is Wasteful and “Less” is Worse in Low AMH Protocols
For individuals navigating the emotionally exhausting landscape of In Vitro Fertilization (IVF)—particularly those diagnosed with low Anti-Müllerian Hormone (AMH) or diminished ovarian reserve (DOR)—the internet can feel like a battleground of conflicting advice. On one side, some clinics push massive, aggressive doses of medications under the assumption that a failing ovarian response simply requires more horsepower. On the other side, an equally vocal contingent advocates for “mini-IVF” or mild stimulation protocols, using the comforting but biologically flawed mantra that “less is better.”
When facing the profound distress of a failed cycle, patients are highly vulnerable to these marketing narratives. However, reproductive medicine—like all pharmacology—is governed by strict biological rules, not emotional sentiment. In medicine, standard pharmacology follows a predictable dose-response curve. Sub-therapeutic dosing does not improve clinical outcomes, just as a lower dose of an antibiotic, Tylenol®, or chemotherapy would fail to clear an infection, break a fever, or destroy a tumor. Conversely, throwing excess medication at a receptor that is already saturated is often disappointing and leads to added expense.
To find clarity, we must peel back the commercial names, look at the actual physiological molecules at play, examine the landmark randomized controlled trials, and bust the persistent myths surrounding “add-on” therapies like Growth Hormone (GH), CoQ10, and DHEAS.
The Biological Truth: There Are Only Three Effective Hormones
Despite the dizzying array of brand names lining the shelves of specialty pharmacies—such as Gonal-F®, Follistim®, and Menopur®—the entire biological mechanism of ovarian stimulation relies on exactly three fundamental endocrine molecules: Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), and Estradiol (Estrogen).
- FSH (Follicle-Stimulating Hormone): This hormone binds directly to the granulosa cells surrounding your resting follicles, signaling them to grow, mature, and produce estrogen.
- LH (Luteinizing Hormone): This hormone acts on the surrounding theca cells to provide the structural building blocks (androgens) that the granulosa cells convert into estrogen, supporting final egg maturation.
- Estradiol (Estrogen) and the Role of Estrogen Priming: Beyond baseline function, estradiol plays a critical clinical role in sensitizing FSH receptors. By administering oral or transdermal estradiol during the late luteal phase of the preceding cycle, clinicians can temporarily suppress the natural, premature rise of baseline FSH and allow time for the upregulation of FSH receptors before starting stimulation. Clinical evidence shows that this step significantly helps poor responders grow follicles at a better rate, lowering cycle cancellation rates and improving clinical pregnancy rates (Reynolds et al., 2020).
Every single injection protocol used globally is merely a variation, combination, or unique delivery vehicle for these three molecules. There is no “secret magic hormone” or vitamin that can magically create or improve egg DNA. While not a perfect indicator, your AMH level predicts the most likely maximum number of eggs available for recruitment in any given month. If your reserve is very low, no combination or brand variation of FSH and LH can force the ovary to produce a good response. Ovarian reserve is not the same every cycle, and having one bad cycle does not mean it will happen every time; however, the chance for success remains the same when the exact same protocol is used twice. In other words: it is not the protocol.
The Ceiling Effect: Why “Higher is Not Better”
When a patient exhibits a poor response to initial stimulation, a common knee-jerk reaction is to escalate the gonadotropin dose to extreme levels, such as 450 IU to 600 IU per day. Physicians often do this with the best of intentions. However, extensive clinical trials confirm that the human ovary suffers from a strict biological plateau known as the receptor saturation ceiling.
Once all available FSH and LH receptors on the granulosa cells are fully occupied, adding more medication provides zero therapeutic return. The excess hormone simply circulates in the bloodstream unutilized, driving up the patient’s financial burden, injection discomfort, and systemic side effects without retrieving a single additional egg.
This biological reality has been proven across multiple major studies:
- The Kovacs et al. Multicenter RCT (2025): This randomized controlled trial evaluated expected poor-prognosis patients meeting POSEIDON criteria. Patients were randomized to receive either a standard dose of 225 IU/day or an escalated high dose of 375 IU/day. The study concluded that maximizing the dose yielded absolutely no improvement in mature (MII) oocyte counts, clinical pregnancy rates, or cumulative live birth rates (Kovacs et al., 2025).
- The Lensen & Griesinger RCT (2021): This trial compared a conventional 150 IU/day starting regimen directly against an aggressive high-dose 450 IU/day regimen in poor responders. The final number of retrieved oocytes and overall live birth rates were nearly identical. The high-dose protocol dramatically drove up blood hormone levels but completely failed to improve cellular function, proving that pushing doses past the saturation threshold is clinically useless.
- The Cochrane Systematic Review (2021): A sweeping meta-analysis compiling data across dozens of randomized controlled trials confirmed that conventional high doses (greater than 300–450 IU/day) show no statistical superiority in live birth rates compared to standard regimens (Cochrane Database, 2021).
The Starvation Effect: Why “Lower is Worse”
Because high doses fail to smash through the biological ceiling, a counter-movement has emerged claiming that “less is better” or that mild stimulation somehow improves egg quality (DNA). This claim is highly misleading. While “higher is not better” due to receptor saturation, dropping the dosage below the necessary therapeutic threshold creates a catastrophic “starvation effect.”
When a patient has a low AMH, the pool of remaining follicles is already profoundly depleted. To ensure that every single one of those few remaining follicles receives an adequate signal to grow simultaneously, a robust, steady baseline of stimulation is mandatory. If you drop the dosage too low (as seen in mini-IVF or mild protocols of 75–150 IU/day), you fail to meet the basic threshold required to rescue those depleted follicles from natural cell death (atresia).
A landmark study published in the Journal of Assisted Reproduction and Genetics explicitly exposed the dangers of under-treating this fragile patient demographic (Le et al., 2022). The study evaluated 359 extreme poor responders meeting POSEIDON Group 4 criteria (AMH less than 1.2 ng/mL, AFC less than 5) and compared mild stimulation directly to conventional protocols.
The data was definitive: in women with an Antral Follicle Count (AFC) less than or equal to 3, the mild stimulation regimen resulted in significantly poorer clinical outcomes compared to the conventional 450 IU protocol. Under-stimulating these patients yielded:
- Fewer overall follicles
- Fewer mature (MII) eggs retrieved
- A lower number of day-2 embryos
- Significantly fewer top-quality embryos
Dropping the dose too low does not magically enhance egg quality; it simply starves the few viable follicles you have, leading to preventable cycle failures and severe clinical disappointment.
The Growth Hormone Myth: Debunking the Hype
Another highly commercialized “add-on” frequently marketed to desperate poor responders is human Growth Hormone (GH). Proponents claim that GH is a critical, missing limiting factor required to optimize egg quality and ovarian response.
To understand why this is a biological fallacy, we can look to classic human genetics. If growth hormone were a mandatory, critical limiting factor for oocyte development and female fertility, individuals with Laron syndrome or isolated growth hormone deficiency (patients of extreme short stature with zero or entirely non-functional GH production) would be completely sterile. Yet, medical history and genetic registries demonstrate that these individuals are fully capable of conceiving and carrying healthy children naturally without any GH intervention. Reproductive biology functions independently of systemic growth hormone.
While GH can play a secondary role in modulating local insulin-like growth factors (IGF-1) within the ovary, large-scale, well-designed randomized trials show that adding expensive GH injections to an IVF cycle does not statistically improve live birth rates. It is an expensive add-on that exploits a patient’s emotional distress rather than delivering true medical efficacy.
Conclusion: Trust the Science, Avoid Marketing Pitfalls
When navigating an IVF cycle with a low AMH, the data clearly defines a narrow “sweet spot.” Pushing the daily gonadotropin dose to extreme highs provides no benefit because your hormone receptors hit a definitive biological ceiling. However, starving those same receptors with an overly timid, mild, or “mini” protocol is actively detrimental, resulting in fewer mature eggs and a lower count of high-quality embryos. What was sold as a more cost-effective option results in more costly treatment in the long run due to repeated failed cycles.
The ideal protocol is a balanced, therapeutic, conventional dosage designed to fully saturate your available receptors without wasteful excess. IVF is a journey governed by precise clinical evidence. Patients deserve protocols built on reproducible, peer-reviewed science—free from false promises, commercial gimmicks, and sub-therapeutic under-treatment.
References
- Cochrane Review Reference: National Center for Biotechnology Information (2021). Gonadotrophin dosing for human in vitro fertilization: a systematic overview. PubMed Central, PMC7902993.
- Kovacs Study Reference: Kovacs, P., Nagy, D. U., Boga, P., Zadori, J., Sandfeld, E., & Lindheim, S. R. (2025). Increased gonadotropin dosing (375 vs 225 IU/day) does not improve clinical outcomes in poor-prognosis patients undergoing IVF: results of a multi-center randomized controlled trial. Journal of IVF-Worldwide, 3(4), 1-13.
- Le / Poseidon Study Reference: Le, K., et al. (2022). Comparative Effectiveness of Mild or Conventional GnRH-Antagonist Protocols for Ovarian Stimulation in Poor Responders (Poseidon Group 4). PubMed Central, PMC9580736.
- Lensen Study Reference: Lensen, S. F., & Griesinger, G. (2021). Dose of gonadotropins for ovarian stimulation in IVF: an old question with clear answers. Human Reproduction, 36(5), 1189–1195.
- Reynolds / Estrogen Priming Reference: Reynolds, K. A., et al. (2020). Estrogen priming in random-start and conventional gonadotropin-releasing hormone antagonist protocols for poor responders: a systematic review and meta-analysis. Fertility and Sterility, 114(1), 115-123.
